The authors conclude that clonally derived heart progenitor cells have potential for therapeutic use in the regeneration of damaged heart tissues, as these cells offer the possibility of matching ...

The adult mammalian myocardium has a robust intrinsic regenerative capacity because of the presence of cardiac stem cells (CSCs). Despite being mainly composed of terminally differentiated ...

STM-01 is an allogeneic neonatal cardiac progenitor cell (nCPC) therapy designed to treat various inflammatory cardiovascular diseases such as HFpEF. The Fast Track designation was based on STM-01 ...

driven by the secretion of VEGFA protein from iPS-derived cardiac pericyte progenitor cells. More information: Yutaro Miyoshi et al, SMAD3 mediates the specification of human induced pluripotent ...

These progenitor cells, derived from human heart tissue, were developed by Marbán over many years of work. “Although this Smidt Heart Institute study was performed on animals, its findings have ...

Secretome Therapeutics is developing therapies derived from neonatal cardiac progenitor cells (nCPCs) to address life-threatening cardiovascular diseases and conditions driven by inflammation.

You’ve viewed 1 of 5 articles this month. If you wish to read unlimited content, please log in or register below. Registration is free.

the company’s neonatal cardiac progenitor cell (nCPC) therapy, for the treatment of Heart Failure with Preserved Ejection Fraction (HFpEF).